门静脉系统癌栓的来源及诊疗进展

胡牧仁; 葛步军

doi:10.3969/j.issn.1001-5256.2018.10.006

门静脉系统癌栓的来源及诊疗进展

DOI: 10.3969/j.issn.1001-5256.2018.10.006

上海市同济医院普外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2354
- HTML全文浏览量: 10
- PDF下载量: 410
- 被引次数: 0
出版历程
- 出版日期: 2018-10-20

Source of portal vein tumor thrombosis and advances in its diagnosis and treatment

Hu MuRen,
Ge BuJun

Department of General Surgery, Shanghai Tongji Hospital

摘要

摘要: 门静脉系统癌栓是影响恶性肿瘤患者治疗方式以及预后的重要因素之一,门静脉系统癌栓的早期诊断和治疗对于改善患者预后具有重要意义,然而现阶段针对门静脉系统癌栓的诊断及治疗仍未形成规范、统一的指南。就门静脉系统癌栓的来源及诊疗进展进行综述。
- 肿瘤 /
- 栓塞 /
- 门静脉 /
- 诊断 /
- 治疗学
Abstract: Portal vein tumor thrombosis is one of the important factors that affect the treatment and prognosis of patients with malignancies.The early diagnosis and treatment of portal vein tumor thrombosis is of great significance to improve the prognosis of patients. However, at present, there is no standard and unified guideline for the diagnosis and treatment of portal vein tumor thrombosis. This article reviews the source as well as the advances in diagnosis and treatment of portal vein tumor thrombosis.
- neoplasms /
- embolism /
- portal vein /
- diagnosis /
- therapeutics

HTML全文

参考文献(63)

[1]CHAN SL, CHONG CC, CHAN AW, et al.Management of hepatocellular carcinoma with portal vein tumor thrombosis:Review and update at 2016[J].World J Gastroenterol, 2016, 22 (32) :7289-7300.

[2]RINGE B, PICHLMAYR R, WITTEKIND C, et al.Surgical treatment of hepatocellular carcinoma:Experience with liver resection and transplantation in 198 patients[J].World J Surg, 1991, 15 (2) :270-285.

[3]LLOVET JM, BUSTAMANTE J, CASTELLS A, et al.Natural history of untreated nonsurgical hepatocellular carcinoma:Rationale for the design and evaluation of therapeutic trials[J].Hepatology, 2010, 29 (1) :62-67.

[4]ARAKI T, SUDA K, SEKIKAWA T, et al.Portal venous tumor thrombosis associated with gastric adenocarcinoma[J].Radiology, 1990, 174 (1) :811-814.

[5]KANEKO T, NAKAO A, ENDO T, et al.Intraportal tumor thrombus of gallbladder carcinoma:Detection with intravascular ultrasonography[J].Am J Gastroenterol, 1996, 91 (6) :1268-1269.

[6]MATSUMOTO J, KOJIMA T, HIRAGUCHI E, et al.Portal vein tumor thrombus from colorectal cancer with no definite metastatic nodules in liver parenchyma[J].J Hepatobiliary Pancreat Surg, 2009, 16 (5) :688-691.

[7]SIMONETTI RG, LIBERATI A, ANGIOLINI C, et al.Treatment of hepatocellular carcinoma:A systematic review of randomized controlled trials[J].Ann Oncol, 1997, 8 (2) :117-136.

[8]AOKI T, KUBOTA K.Preoperative portal vein embolization for hepatocellular carcinoma:consensus and controversy[J].World JHepatol, 2016, 8 (9) :439-445.

[9]HEMMING AW, REED AI, HOWARD RJ, et al.Preoperative portal vein embolization for extended hepatectomy[J].Ann Surg, 2003, 237 (5) :691-693.

[10]WANG X, INTERVENTION DO.Effect of serum HIF-1a and VEGF levels on the prognosis of patients with HCC intervention[J].J Med Imaging, 2017.[Epub ahead of print]

[11]LI ZF, CHEN XP, ZHANG WG.Significance of expression of platelet derived growth factor and survivin of hepatocellular carcinoma with portal vein tumor thrombosis[J].Chin J Bases Clin General Surg, 2007, 14 (1) :46-48. (in Chinese) 李哲夫, 陈孝平, 张万广.肝细胞癌合并门静脉癌栓组织中PDGF和survivin表达的意义[J].中国普外基础与临床杂志, 2007, 14 (1) :46-48.

[12]XUE Q, YANG ZQ, XU CW, et al.Prognostic factors of resectable hepatocellular carcinoma with portal vein tumor thrombus[J].Modern Prevent Med, 2018, 45 (2) :360-363. (in Chinese) 薛谦, 杨中秋, 徐春伟, 等.可切除肝癌伴门静脉癌栓的预后影响因素分析[J].现代预防医学, 2018, 45 (2) :360-363.

[13]XU HW.Prospect in effect of cell adhesion and cell adhesion molecules on invasion of carcinoma[J].World Chin J Dig, 2005, 13 (17) :2057-2060. (in Chinese) 许洪卫.细胞黏附力和黏附分子对癌侵袭性影响的研究展望[J].世界华人消化杂志, 2005, 13 (17) :2057-2060.

[14]GIANNELLI G, PIERRI F, TREROTOLI P, et al.Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival:A retrospective clinical study of 150 cases[J].Hepatol Res, 2002, 24 (1) :50-59.

[15]KANAI Y, USHIJIMA S, HUI AM, et al.The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas[J].Int J Cancer, 2015, 71 (3) :355-359.

[16]ZHU XW, GONG JP.Expression and role of icam-1 in the occurrence and development of hepatocellular carcinoma[J].Asian Pac JCancer Prev, 2013, 14 (3) :1579-1583.

[17]CHEN R, CUI J, XU C, et al.The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection[J].Ann Surg Oncol, 2012, 19 (Suppl 3) :s375-s384.

[18]HALAMKOVA J, KISS I, PAVLOVSKY Z, et al.Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients[J].Hepatogastroenterology, 2011, 58 (112) :1918-1925.

[19]KLOECKNER R, MAEHRINGER-KUNZ A, SANTOS DPD, et al.Portal vein tumor thrombosis has a direct impact on liver function[J].J Hepatol, 2018, 68:s209-s210.

[20]FURUSE J, MATSUTANI S, YOSHIKAWA M, et al.Diagnosis of portal vein tumor thrombus by pulsed Doppler ultrasonography[J].J Clin Ultrasound, 2010, 20 (7) :439-446.

[21]ZHANG FJ, LI CX, JIAO DC, et al.CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma[J].Chin Med J (Engl) , 2008, 121 (23) :2410-2414.

[22]YANG WB, LU CY, YANG HY, et al.The value of MRI in identifying portal vein tumor thrombus and portal venous thrombosis in hepatocellular carcinoma patient[J].China Mod Doct, 2016, 54 (11) :92-95. (in Chinese) 杨伟斌, 卢陈英, 杨宏远, 等.MRI在原发性肝细胞癌门静脉癌栓与血栓鉴别中的应用价值[J].中国现代医生, 2016, 54 (11) :92-95.

[23]LI C, HU J, ZHOU D, et al.Differentiation of bland from neoplastic thrombus of the portal vein in patients with hepatocellular carcinoma:Application of susceptibility-weighted MR imaging[J].BMC Cancer, 2014, 14 (1) :1-7.

[24]SHI J, LAI EC, LI N, et al.A new classification for hepatocellular carcinoma with portal vein tumor thrombus[J].J Hepatobiliary Pancreat Sci, 2011, 18 (1) :74-80.

[25]TANG ZY, WANG W, DU G, et al.Analysis of several therapeutic methods to treat primary hepatocellular carcinoma with portal vein tumor thrombus[J].Chin J Hepatobiliary Surg, 2015, 21 (1) :18-88. (in Chinese) 唐振宇, 王伟, 杜刚, 等.原发性肝癌合并门静脉癌栓不同治疗方法的疗效分析[J].中华肝胆外科杂志, 2015, 21 (1) :18-88.

[26]MAZZAFERRO V, REGALIA E, DOCI R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med, 1996, 334 (11) :693-699.

[27]ZHENG SS, XU X, YU J, et al.Orthotopic liver transplantation for hepatocellular carcinoma with portal vein tumor thrombi[J].Chin JPract Surg, 2004, 24 (9) :540-542. (in Chinese) 郑树森, 徐骁, 俞军, 等.肝移植治疗肝细胞癌合并门静脉癌栓的临床价值[J].中国实用外科杂志, 2004, 24 (9) :540-542.

[28]ZHEN H, GAO W, ZHU ZJ, et al.Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus[J].Chin JOrgan Transplant, 2009, 30 (8) :484-486. (in Chinese) 郑虹, 高伟, 朱志军, 等.肝移植治疗肝细胞癌合并门静脉癌栓的疗效评价[J].中华器官移植杂志, 2009, 30 (8) :484-486.

[29]BAN D, SHIMADA K, YAMAMOTO Y, et al.Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein[J].Gastroenterology, 2009, 13 (11) :1921-1928.

[30]CHOK KS, CHEUNG TT, CHAN SC, et al.Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J].World J Surg, 2014, 38 (2) :490-496.

[31]FORNER A, LLOVET JM, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2012, 379 (9822) :1245-1255.

[32]OMATA M, LESMANA LA, TATEISHI R, et al.Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma[J].Hepatol Int, 2010, 4 (2) :439-474.

[33]LEE HS, KIM JS, CHOI IJ, et al.The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction.A prospective controlled study[J].Cancer, 2015, 79 (11) :2087-2094.

[34]CHUNG GE, LEE JH, KIM HY, et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J].Radiology, 2011, 258 (2) :627-634.

[35]LUO J, GUO RP, LAI EC, et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:A prospective comparative study[J].Ann Surg Oncol, 2011, 18 (2) :413-420.

[36]XUE TC, XIE XY, LAN Z, et al.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus:a meta-analysis[J].BMC Gastroenterol, 2013, 13 (1) :60.

[37]BAE BK, KIM JC.The response of thrombosis in the portal vein or hepatic vein in hepatocellular carcinoma to radiation therapy[J].Radiat Oncol J, 2016, 34 (3) :168-176.

[38]CHAI HR, YANG DS, PARK YJ, et al.Effectiveness of highdose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis[J].Jpn J Clin Oncol, 2012, 42 (8) :721-729.

[39]LEE D, LEE HC, AN J, et al.Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion[J].Clin Mol Hepatol, 2018, 56 (3) :1-9.

[40]BIEDERMAN DM, TITANO JJ, TABORI NE, et al.Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion:resin versus glass microspheres[J].J Vasc Interv Radiol, 2016, 27 (6) :812-821.e2.

[41]JIA Z, JIANG G, TIAN F, et al.A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis[J].Saudi J Gastroenterol, 2016, 22 (5) :353-359.

[42]LIAO YY, ZHONG JH, PENG NF, et al.Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?[J].Liver Int, 2016, 36 (11) :1715.

[43]CHEN DS, WU GX, CHEN DX.Chemotherapy of FOLFOX 4 combined with radiofrequency ablation for the treatment of hepatocellularcar cinoma[J].China Prac Med, 2014, 9 (15) :13-15. (in Chinese) .陈东升, 吴光兴, 陈德雄, 等.FOLFOX4方案化疗联合射频消融治疗原发性肝癌[J].中国实用医药, 2014, 9 (15) :13-15.

[44]QIN S, BAI Y, LIM HY, et al.Randomized, multicenter, openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol, 2013, 31 (28) :3501-3508.

[45]CHAN SL.Drug development for hepatocellular carcinoma:knowing the past helps to understand the future[J].Oncologist, 2014, 19 (11) :1115-1117.

[46]LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (23) :378-390.

[47]JEONG SW, JANG JY, SHIM KY, et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver, 2013, 7 (6) :696-703.

[48]GIORGIO A, MEROLA MG, MONTESARCHIO L, et al.Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein:Awestern randomized controlled trial[J].Anticancer Res, 2016, 36 (11) :6179-6183.

[49]SONG DS, SONG MJ, BAE SH, et al.A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].J Gastroenterol, 2015, 50 (4) :445-454.

[50]YAMAKADO K, TANAKA N, NAKATSUKA A, et al.Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein[J].J Hepatol, 1999, 30 (4) :660-668.

[51]VIBERT E, AZOULAY D, CUNHA AS, et al.Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients.[J].J Surg Oncol, 2013, 107 (7) :696-701.

[52]HIROOKA M, KOIZUMI Y, KISAKA Y, et al.Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus[J].AJR Am J Roentgenol, 2010, 194 (2) :221-226.

[53]CHEN ZW, LIN ZY, CHEN YP, et al.Clinical efficacy of endovascular radiofrequency ablation in the treatment of portal vein tumor thrombus of primary hepatocellular carcinoma[J].J Cancer Res T-her, 2018, 14 (1) :145-149.

[54]SUN B, LUO M, LU Z, et al.Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus[J].Clin Appl Thromb Hemost, 2010, 16 (6) :694-697.

[55]MEARINI L.High intensity focused ultrasound, liver disease and bridging therapy[J].World J Gastroenterol, 2013, 19 (43) :7494-7499.

[56]ZHONG JH, RODRGUEZ AC, KE Y, et al.Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion[J].Medicine (Baltimore) , 2015, 94 (3) :e396.

[57]CHITAPANARUX T, PHORNPHUTKUL K.Risk factors for the development of hepatocellular carcinoma in Thailand[J].J Clin Transl Hepatol, 2015, 3 (3) :182-188.

[58]LI N, FENG S, XUE J, et al.Hepatocellular carcinoma with main portal vein tumor thrombus:a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J].HPB, 2016, 18 (6) :549-556.

[59]PENG BG, HE Q, LI JP, et al.Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J].Am JSurg, 2009, 198 (3) :313-318.

[60]ZHU K, CHEN J, LAI L, et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study[J].Radiology, 2014, 272 (1) :284-293.

[61]LONG J, ZHENG JS, SUN B, et al.Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization:a prospective study[J].Hepatol Int, 2016, 10 (1) :175-184.

[62]NAGAI H, MUKOZU T, OGINO YU, et al.Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus[J].Anticancer Res, 2015, 35 (4) :2269-2277.

[63]KANG W, WEI XG, MIN SC, et al.Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus:A large-scale, multicenter, propensity mathching score analysis[J].Medicine, 2016, 95 (11) :e3015.

施引文献

资源附件(0)

访问统计